Regulatory Exclusivity. On a Product-by-Product and country-by-country basis, if the sole basis for the continuance of a Royalty Term is the existence of Regulatory Exclusivity, the applicable royalty rate under Section 4.1 shall be reduced by fifty percent (50%).
Appears in 4 contracts
Sources: Termination and Revised Relationship Agreement (MEI Pharma, Inc.), Termination and Revised Relationship Agreement (MEI Pharma, Inc.), Termination and Revised Relationship Agreement (Infinity Pharmaceuticals, Inc.)